Table: Anges - 9-MTH group results
Oct 30 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2017 Sep 30, 2016 Dec 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 255 mln 256 mln 360 mln
(-0.4 pct) (-19.9 pct)
Operating loss 2.74 loss 3.76 loss 3.40
Recurring loss 2.76 loss 3.81 loss 3.40
Net loss 3.36 loss 3.82 loss 3.40
EPS loss 44.64 yen loss 62.66 yen loss 45.18 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001